Table 7.
Results: sensitivity analyses
| Combination therapy v no treatment | Combination therapy v monotherapy | |||||
| Sensitivity analysis | Marginal cost (£) | Marginal effectiveness (QALY) | Marginal cost effectiveness (£/QALY) | Marginal cost (£) | Marginal effectiveness (QALY) | Marginal cost effectiveness (£/QALY) |
| Reduce cost of combination therapy by 50% | 1313 | 1.21 | 1084 | −683 | 0.74 | Dominated |
| Increase cost of combination therapy by 50% | 7866 | 1.21 | 6497 | 5871 | 0.74 | 7887 |
| Reduce cost of treating consequences of HCV infection by 50% | 5571 | 1.21 | 4602 | 3286 | 0.74 | 4415 |
| Increase cost of treating consequences of HCV infection by 50% | 3607 | 1.21 | 2980 | 1902 | 0.74 | 2555 |
| Reduce annual likelihood of progressive liver disease by 50% | 5385 | 0.71 | 7617 | 3072 | 0.44 | 7039 |
| Increase annual likelihood of progressive liver disease by 50% | 3847 | 1.68 | 2286 | 2151 | 1.03 | 2081 |
QALY, quality adjusted life year.